Search
for
Sort by
Research 181–210 of 303
- Efficacy of Tofacitinib in the Treatment of Universal Alopecia Areata and Primary Sjögren Syndrome
- Which is the ideal JAK inhibitor for alopecia areata – Baricitinib, tofacitinib, ritlecitinib or ifidancitinib - Revisiting the immunomechanisms of the JAK pathway
- Alopecia areata and risk of atopic and autoimmune conditions: population-based cohort study
- The associated burden of mental health conditions in alopecia areata: a population‐based study in UK primary care*
- Lifetime incidence and healthcare disparities in alopecia areata: a UK population-based cohort study
- Alopecia areata
- From mechanisms to therapies: current advances breakthroughs in alopecia areata immunopathology
- Ritlecitinib for Severe Alopecia Areata: A 24-Week, Multicentre, Real-World Study
- Chemotherapy-Induced Alopecia Beyond Cytotoxicity: Hair Follicle Immune Privilege Collapse and JAK-STAT Signaling
- Rates of Infections, Malignancies, Cardiovascular Outcomes, and Death in Individuals with Hospital-treated Alopecia Areata: A Registry-based Cohort Study in Denmark
- Gene-Environment Interaction Between <i>CYP1B1</i> and Oral Contraception on Frontal Fibrosing Alopecia
- A retrospective analysis of disease epidemiology, comorbidities, treatment patterns, and healthcare resource utilization of alopecia areata in the United Arab Emirates using claims database
- Alopecia Areata: An Updated Review for 2023
- Dermatologist and Patient Perceptions of Treatment Success in Alopecia Areata and Evaluation of Clinical Outcome Assessments in Japan
- Inhibition of T-cell activity in alopecia areata: recent developments and new directions
- An Evaluation of Generic and Disease‐Specific Patient‐Reported Outcome Measures to Assess the Impact of Percentage of Scalp Hair Loss on Health‐Related Quality of Life in a European Population
- Correlation of trichoscopic findings with clinico-epidemiological factors in male pattern&nbsp;<span style="font-size: 1rem;">hairloss: A cross-sectional study from a tertiary care center in Chengalpattu</span>
- Selective blockade of γc pathway ameliorates alopecia areata in a humanized murine model
- Efficacy and predictive markers of response to tofacitinib and baricitinib therapy in alopecia areata: A 52-week comparative cohort study
- JAK-Inhibitors Beyond the Label: Emerging Applications in Dermatology
- Alopecia in Children
- Advancements in Bioactive Compounds and Therapeutic Agents for Alopecia: Trends and Future Perspectives
- Systemic Treatment of Moderate to Severe Alopecia Areata in Adults: Updated Australian Expert Consensus Statement
- Significant efficacy of tofacitinib from China in the treatment of alopecia areata: a case report
- Recent Advances in Drug Development for Hair Loss
- Generic vs. Disease-Specific Patient Reported Outcome (PRO) Instruments for Assessing HRQoL Burden Among Patients Diagnosed with Alopecia Areata: Evidence from TARGET-DERM AA
- The Epidemiology of Hospital-Treated Alopecia Areata in Denmark, 1995–2016
- Hair Disorders in Autoimmune Diseases
- Scalp Microinfusion: A Novel Drug Delivery Technique for Hair Loss Treatment
- Comparative Efficacy of JAK Inhibitors in Acute vs Nonacute Alopecia Areata: A Retrospective Cohort Study